Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...